The generic name for Cibinqo is abrocitinib [1].
What is abrocitinib used for?
Abrocitinib is a medication used to treat moderate to severe atopic dermatitis (eczema) in adults [1]. It is also being investigated for other conditions.
How does abrocitinib work?
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor [1]. By inhibiting JAK1, it helps to reduce inflammation that contributes to atopic dermatitis.
When did abrocitinib become available?
Abrocitinib received its first FDA approval in December 2021 [2].
Who makes Cibinqo (abrocitinib)?
Cibinqo is developed and marketed by Pfizer [1].
What are the potential side effects of abrocitinib?
Common side effects of abrocitinib include upper respiratory tract infections, nausea, headache, and increased blood creatine phosphokinase [1]. More serious risks can include infections, major adverse cardiovascular events, thrombosis, and certain types of cancer [1].
How does abrocitinib compare to other eczema treatments?
Abrocitinib is a targeted therapy that works differently than topical treatments like corticosteroids. It is an oral medication, offering an alternative to injectable biologic drugs for some patients with moderate to severe eczema. Comparisons often focus on efficacy, safety profiles, and administration methods with other JAK inhibitors and biologics used for atopic dermatitis.
What is the patent status for abrocitinib?
Information on the specific patent landscape for abrocitinib, including expiry dates and any ongoing litigation, can be found on specialized drug patent tracking websites like DrugPatentWatch.com [3].
What are the next steps for abrocitinib research?
Research for abrocitinib continues to explore its efficacy and safety in different patient populations and for other inflammatory conditions beyond atopic dermatitis.
---
Sources:
1. https://www.drugpatentwatch.com/
2. U.S. Food & Drug Administration. (2021, December 20). FDA approves Cibinqo (abrocitinib) for the treatment of adults with atopic dermatitis. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cibinqo-abrocitinib-treatment-adults-atopic-dermatitis
3. DrugPatentWatch.com. (n.d.). Abrocitinib Patents. Retrieved from https://www.drugpatentwatch.com/